Navigation Links
Stereotaxis Receives Commitment to Increase and Extend Credit Facility
Date:11/10/2010

ST. LOUIS, Nov. 10, 2010 /PRNewswire-FirstCall/ -- Stereotaxis, Inc. (Nasdaq: STXS) announced today that the Company has received a commitment letter from Silicon Valley Bank for an amended credit agreement that extends its revolving $30 million credit facility to March 31, 2012.  Consistent with the current agreement, the revolving line of credit commitment includes a sublimit of $10 million for advances guaranteed by two current shareholders.  The commitment also provides an additional $10 million term loan that matures on January 1, 2014.

"Our two primary objectives in negotiating an amendment to the facility were to extend the current revolving facility to March of 2012 and to obtain a longer maturity term loan to bridge the Company's capital structure through the repayment of other obligations due by the end of 2011.  This combined facility allows for additional financial flexibility as we continue to focus on driving commercial success of our technology platforms," said Mike Kaminski, Chief Executive Officer of Stereotaxis.

The commitment is contingent upon the Company raising $10 million in additional equity, completion of definitive loan documents and other typical closing conditions as well as the recently completed extension of the $10 million guarantee from two shareholders. Stereotaxis reached an agreement with these shareholders to extend their guarantee through March 31, 2012 in exchange for warrants to purchase an aggregate of 800,000 shares of Stereotaxis common stock.  The exercise price of these shares will be the greater of 10% above the November 2010 underwritten offering price or the closing bid price on November 10, 2010.

About Stereotaxis

Stereotaxis designs, manufactures and markets an advanced cardiology instrument control system for use in a hospital's interventional surgical suite to enhance the treat
'/>"/>

SOURCE Stereotaxis, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Stereotaxis Awarded $1.5 Million in Grants under the Qualifying Therapeutic Discovery Project Program
2. Stereotaxis Reports Third Quarter Financial Results
3. Stereotaxis Appoints Industry Veteran as Head of EMEA Sales and Operations
4. Stereotaxis Announces Third Quarter 2010 Earnings Release Date and Conference Call
5. Stereotaxis Launches the Odyssey Interventional Network for Superior Online Cardiovascular Education and Training
6. Stereotaxis Announces Third Quarter 2010 Capital Orders of $12.2 Million, Up 94 Percent Year-to-Year
7. Stereotaxis to Present at the JMP Securities Healthcare Conference
8. Stereotaxis Achieves Intellectual Property Milestone With 100th U.S. Patent
9. Stereotaxis to Present at the CL King Best Ideas Conference and the Stifel Nicolaus Healthcare Conference
10. Stereotaxis Announces First-Ever, Prospective, Comparative Clinical Trial Outcome for VT Patients
11. Stereotaxis Announces Second Quarter 2010 Earnings Release Date and Conference Call
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... 2014 Valeritas, Inc., a leader in simple, ... Type 2 diabetes, announced today that it has received ... award was presented October 16 th at Cardinal,s ... . The Cardinal Health Supply ... of metrics specifically targeted at the importance of developing ...
(Date:10/20/2014)...  AnaptysBio, Inc., a leader in the discovery ... appointment of Marco Londei , M.D. as ... preclinical and clinical development of AnaptysBio,s proprietary antibody ... welcome Dr. Londei to AnaptysBio,s executive leadership team," ... Executive Officer of AnaptysBio. "Dr. Londei,s extensive expertise ...
(Date:10/20/2014)... Lpath, Inc. (NASDAQ: LPTN ... official notification from the European Patent Office that ... supporting its iSONEP™ and ASONEP™ programs. ... 2087002, claims compositions of matter related to sonepcizumab, ... iSONEP and ASONEP. Sonepcizumab is an antibody that ...
Breaking Medicine Technology:Valeritas Receives 2014 Cardinal Health Supply Chain Excellence Award 2Valeritas Receives 2014 Cardinal Health Supply Chain Excellence Award 3AnaptysBio Appoints Dr. Marco Londei to Newly Created Chief Development Officer Position Clinical Immunologist to Lead AnaptysBio's Pipeline Advancement 2Lpath Granted Key European Patent Related to iSONEP and ASONEP Programs 2Lpath Granted Key European Patent Related to iSONEP and ASONEP Programs 3Lpath Granted Key European Patent Related to iSONEP and ASONEP Programs 4
... ... ... ... ...
... ... ... ... ...
Cached Medicine Technology:KAPIDEX(TM) (dexlansoprazole) Renamed DEXILANT(TM) in U.S. to Avoid Name Confusion 2KAPIDEX(TM) (dexlansoprazole) Renamed DEXILANT(TM) in U.S. to Avoid Name Confusion 3KAPIDEX(TM) (dexlansoprazole) Renamed DEXILANT(TM) in U.S. to Avoid Name Confusion 4KAPIDEX(TM) (dexlansoprazole) Renamed DEXILANT(TM) in U.S. to Avoid Name Confusion 5KAPIDEX(TM) (dexlansoprazole) Renamed DEXILANT(TM) in U.S. to Avoid Name Confusion 6STELARA(TM) and REMICADE(R) Data in Treatment of Plaque Psoriasis to be Presented at American Academy of Dermatology (AAD) Meeting 2STELARA(TM) and REMICADE(R) Data in Treatment of Plaque Psoriasis to be Presented at American Academy of Dermatology (AAD) Meeting 3STELARA(TM) and REMICADE(R) Data in Treatment of Plaque Psoriasis to be Presented at American Academy of Dermatology (AAD) Meeting 4STELARA(TM) and REMICADE(R) Data in Treatment of Plaque Psoriasis to be Presented at American Academy of Dermatology (AAD) Meeting 5STELARA(TM) and REMICADE(R) Data in Treatment of Plaque Psoriasis to be Presented at American Academy of Dermatology (AAD) Meeting 6STELARA(TM) and REMICADE(R) Data in Treatment of Plaque Psoriasis to be Presented at American Academy of Dermatology (AAD) Meeting 7STELARA(TM) and REMICADE(R) Data in Treatment of Plaque Psoriasis to be Presented at American Academy of Dermatology (AAD) Meeting 8STELARA(TM) and REMICADE(R) Data in Treatment of Plaque Psoriasis to be Presented at American Academy of Dermatology (AAD) Meeting 9STELARA(TM) and REMICADE(R) Data in Treatment of Plaque Psoriasis to be Presented at American Academy of Dermatology (AAD) Meeting 10STELARA(TM) and REMICADE(R) Data in Treatment of Plaque Psoriasis to be Presented at American Academy of Dermatology (AAD) Meeting 11STELARA(TM) and REMICADE(R) Data in Treatment of Plaque Psoriasis to be Presented at American Academy of Dermatology (AAD) Meeting 12STELARA(TM) and REMICADE(R) Data in Treatment of Plaque Psoriasis to be Presented at American Academy of Dermatology (AAD) Meeting 13STELARA(TM) and REMICADE(R) Data in Treatment of Plaque Psoriasis to be Presented at American Academy of Dermatology (AAD) Meeting 14STELARA(TM) and REMICADE(R) Data in Treatment of Plaque Psoriasis to be Presented at American Academy of Dermatology (AAD) Meeting 15STELARA(TM) and REMICADE(R) Data in Treatment of Plaque Psoriasis to be Presented at American Academy of Dermatology (AAD) Meeting 16STELARA(TM) and REMICADE(R) Data in Treatment of Plaque Psoriasis to be Presented at American Academy of Dermatology (AAD) Meeting 17
(Date:10/20/2014)... ASCNYC (ascnyc.org) is a New ... Yorkers living with HIV/AIDS and other chronic conditions ... and self-sufficiency. Each year, ASCNYC spotlights selected “Positive ... their tireless efforts. , Savills Studley ... been selected as this year’s honoree for sharing ...
(Date:10/20/2014)... October 20, 2014 T.E.N., a ... firm, announced today that William H. Murray, renowned ... 2014 ISE® Luminary Leadership Award winner. Presented annually, ... of an outstanding leader and industry practitioner for ... in advancing the information security industry. , Formerly ...
(Date:10/20/2014)... Zereana Jess-Huff, a 34-year-old mother, corporate executive and ... platform to think outside the bra. She doesn’t try to ... raise awareness about women’s other lady parts. , "We have ... the color pink and everybody knows what you’re talking about,” ... it has not been won when it comes to gynecologic ...
(Date:10/20/2014)... (PRWEB) October 20, 2014 My Clients ... management software application. The new module enables easy ... receive full life-cycle quality care. , This application allows ... within their practice, attach a to-do item to a ... and even set up reoccurring reminders for follow-ups. ...
(Date:10/20/2014)... AttorneyOne.com, a recognized authority on law, update the website ... Sit and Slim II . , The FDA ... Sit and Slim II because it contains Sibutramine ... loss product on various websites and possibly in some retail ... safety reasons, can significantly increase blood pressure and/or pulse rate ...
Breaking Medicine News(10 mins):Health News:Savills Studley's Marc Shapses To Be Honored as 2014 "Positive Changemaker" by ASCNYC 2Health News:Savills Studley's Marc Shapses To Be Honored as 2014 "Positive Changemaker" by ASCNYC 3Health News:Bill Murray named 2014 ISE® Luminary Leadership Award Winner 2Health News:Bill Murray named 2014 ISE® Luminary Leadership Award Winner 3Health News:Bill Murray named 2014 ISE® Luminary Leadership Award Winner 4Health News:Ovarian Cancer Survivor Mrs. Maryland Urges Media to Think Outside the Bra 2Health News:Ovarian Cancer Survivor Mrs. Maryland Urges Media to Think Outside the Bra 3Health News:My Clients Plus Announces New Workflow Management Software 2Health News:FDA Advises Not to Use Sit and Slim II: AttorneyOne Monitors and Keeps Consumers Informed 2
... A recent study by Harvard researchers suggests a link between ... people who received the vaccine were three-times more likely to ... who were not vaccinated. ,While this finding is disturbing, ... the development of MS was small -- 93 percent of ...
... caused by massive skin cancers on the face can be ... of the body. ,Most skin cancers arising on the ... family, and treatment is sought before the cancers get out ... cancers and repair the damage using flaps of skin located ...
... High levels of glycosylated hemoglobin, or HA1c, may be ... heart disease // and stroke, according to the new ... blood sugar control and the development of heart disease ... than 10,000 people, investigators found a 21-percent increase in ...
... friend might be able to detect bladder cancer . With ... malignant tumors in urine samples. ,Six dogs of ... discriminate between urine from patients with bladder cancer and that ... of urine from six control group participants and one bladder ...
... allergens and tobacco smoke could help reduce symptoms of ... than 900 children with asthma were studied. The children ... and lived in low-income areas. Previous research shows children ... at a disproportionately high rate. ,Researchers designed an ...
... even though evidence of its benefits is lacking in ... are no major benefits to surgically removing tonsils and ... examined 300 children, ages 2 to 8, with recurrent ... the children had the surgery, and half were allocated ...
Cached Medicine News:
... Multiplus no rub formula is the most ... All steps in one bottle without the ... your soft contact lenses and removes protein ... multi-purpose solution that contains Hydranate, a special ...
Grafton Trial Frame...
The award-winning new Universal Trial Frame (UB4), the ergonomic refraction design from Oculus that's easier to use, easier to wear....
Half Eye Trial Frame - Adult...
Medicine Products: